{"id":339577,"date":"2026-11-04T17:49:06","date_gmt":"2026-11-04T12:19:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q2-results-fy27-pat-409-crore\/"},"modified":"2026-11-04T17:49:06","modified_gmt":"2026-11-04T12:19:06","slug":"alembic-pharmaceuticals-q2-results-fy27-pat-409-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q2-results-fy27-pat-409-crore\/","title":{"rendered":"Alembic Pharmaceuticals Q2 Results FY27: Net Profit Jumps 121.62% to Rs 409.36 Cr, Revenue Rs 2,391.65 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Alembic Pharmaceuticals Q2 Results FY27 were declared on 4 November 2026. Revenue rose 25.21% YoY to Rs 2,391.65 Cr from Rs 1,910.15 Cr, and net profit rose 121.62% YoY to Rs 409.36 Cr from Rs 184.71 Cr. These quarterly results show YoY growth on both lines, with profit growing faster than revenue.<\/p>\n<\/div>\n

Alembic Pharmaceuticals Ltd<\/a> (APLLTD) Q2 Results FY27 announced on 4 November 2026, covering the company’s financial performance for the July to September quarter. Revenue stood at Rs 2,391.65 Cr and PAT at Rs 409.36 Cr. This note on Alembic Pharmaceuticals Q2 Results FY27 compares both figures with the same quarter a year earlier, and the results date anchors that comparison to the latest filing. Together, these two figures set the scale of the quarter and frame the sections that follow.<\/p>\n

This results analysis of Alembic Pharmaceuticals Q2 Results covers the financial highlights, the business drivers, the outlook and the risks in sequence. The Financial Highlights table that comes next sets each metric of the quarter against the year-ago quarter.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n